Evidence map›Paper›PMID 41561669›Full record

ArticleGynecologic oncology reports2026

Proton beam therapy as an effective treatment option for recurrent endometrial cancer.

Yuta Endo, Yoshiaki Takagawa, Yuki Yoshimoto, Koki Ando, Rei Nishikawa, Masanori Machida, Yuntao Dai, Ichiro Seto, Motohisa Suzuki, Takahiro Kato and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuta EndoDepartment of Gynecology, Southern TOHOKU General Hospital, Fukushima, Japan.
Yoshiaki TakagawaSouthern TOHOKU Proton Therapy Center, Fukushima, Japan.
Yuki YoshimotoDepartment of Gynecology, Southern TOHOKU General Hospital, Fukushima, Japan.
Koki AndoSouthern TOHOKU Proton Therapy Center, Fukushima, Japan.
Rei NishikawaSouthern TOHOKU Proton Therapy Center, Fukushima, Japan.
Masanori MachidaSouthern TOHOKU Proton Therapy Center, Fukushima, Japan.
Yuntao DaiSouthern TOHOKU Proton Therapy Center, Fukushima, Japan.
Ichiro SetoSouthern TOHOKU Proton Therapy Center, Fukushima, Japan.
Motohisa SuzukiSouthern TOHOKU Proton Therapy Center, Fukushima, Japan.
Takahiro KatoSouthern TOHOKU Proton Therapy Center, Fukushima, Japan.
Shigenori FurukawaDepartment of Gynecology, Southern TOHOKU General Hospital, Fukushima, Japan.
Shu SoedaDepartment of Regional Gynecologic Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Keiya FujimoriDepartment of Regional Gynecologic Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Masao MurakamiSouthern TOHOKU Proton Therapy Center, Fukushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate the efficacy and safety of proton beam therapy (PBT) for recurrent endometrial cancer (REC) and to identify predictors of local control (LC). Methods: We retrospectively reviewed REC patients treated with PBT at our institution between 2008 and 2021. LC, progression-free survival (PFS), and overall survival (OS) were estimated using the Kaplan-Meier method, and prognostic factors were analyzed. Toxicities were graded according to CTCAE v5.0. Results: Nine patients with a total of 14 lesions were included (median follow-up, 36.4 months). The 1- and 2-year LC rates were 80.2 % and 68.8 %, respectively. Median PFS and OS were 13.6 and 36.4 months, respectively. Tumor size significantly influenced LC, with lesions < 22.5 mm showing superior outcomes. No grade ≥ 3 toxicities attributable to PBT were observed. Conclusions: These findings suggest that PBT may be a safe and effective salvage treatment for REC, particularly in patients with smaller tumors.

Indexed as

Proton beam therapyRadiation therapyRecurrent endometrial cancer

Identifiers

PMID41561669
PMCPMC12813203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.